ArticleFrontiers in pharmacology2026
From fragmented innovation to an integrated plant-to-product framework: integrated digital twins and artificial intelligence approaches in phytomedicine.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Even in today's scientifically advanced era, phytomedicine still faces challenges regarding raw material authentication, chemical variability, process control, and batch variations. Although robust innovations in artificial intelligence (AI) and digital twins (DTs) are being applied to several medicinal fields, their practical implications in phytomedicine remain fragmented. Researchers are employing AI for the identification of plants, drug likeness, quality predictions, and chemometric analysis, while DTs are used in pharmaceutical manufacturing and controlled environmental agriculture. Therefore, this perspective contends for an integrated AI-assisted plant-to-product-based DT framework, connecting genotypes, medicinal plant cultivation, metabolomic, and chemometric profiling to extraction and final product design. A consistent execution of a planned and well-organized framework warrants authentic raw material alongside a validated analytical procedure, standardized metadata, and robust model validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.